論文 - 詳細
| RRC ID | 59755 |
|---|---|
| 著者 | Takashima Y, Yoshimura T, Kano Y, Hayano A, Hondoh H, Ikenaka K, Yamanaka R. |
| タイトル | Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells. |
| ジャーナル | BMC Cancer |
| Abstract |
BACKGROUND:Oligosaccharides of glycoprotein, particularly negatively-charged sialylated N-glycans, on the surface of lymphomas play important roles in cell-cell interactions and bind immunoglobulin-like lectins, causing inflammatory responses and bioregulation. However, their characterizations have largely been unknown in central nervous system (CNS) lymphoma. METHODS:Here, we investigated expression patterns of N-linked oligosaccharides of glycoproteins in cells derived from CNS lymphomas and clinical specimens. RESULTS:We first generated methotrexate (MTX)-resistant cells derived from HKBML and TK as CNS lymphoma, and RAJI as non-CNS lymphoma and determined N-linked oligosaccharide structures in these cells and other non-CNS lymphoma-derived cells including A4/FUK, OYB, and HBL1. Major components of the total oligosaccharides were high-mannose type N-glycans, whose level increased in MTX-resistant HKBML and TK but decreased in MTX-resistant RAJI. We also detected sialylated biantennary galactosylated N-glycans with α1,6-fucosylation, A2G2F, and A2G2FB from HKBML, TK, and RAJI. Sialylated A4G4F was specifically isolated from RAJI. However, the ratios of these sialylated N-glycans slightly decreased against MTX-resistant compared to non-resistant cells. Interestingly, almost all complex-type oligosaccharides were α2,6-sialylated. DISCUSSION:This is the first study for the expression profile of N-oligosaccharides on MTX-resistant primary CNS lymphoma-derived cells HKBML and TK, and tumor tissues resected from patients with CNS lymphoma, CONCLUSION: These results propose a possibility that the differential expression of high-mannose types and sialylated A2G2F, A2G2FB, and A4G4F on the surface of CNS lymphomas may provide a hint for targets for diagnoses and treatments of the oligosaccharide type-specific lymphomas. |
| 巻・号 | 19(1) |
| ページ | 910 |
| 公開日 | 2019-9-11 |
| DOI | 10.1186/s12885-019-6129-8 |
| PII | 10.1186/s12885-019-6129-8 |
| PMID | 31510952 |
| PMC | PMC6739943 |
| MeSH | Antimetabolites, Antineoplastic / pharmacology* Cell Line, Tumor Cell Proliferation / drug effects Central Nervous System Neoplasms / drug therapy Central Nervous System Neoplasms / genetics* Central Nervous System Neoplasms / metabolism Central Nervous System Neoplasms / pathology Gene Expression Regulation, Neoplastic* Glycoproteins Humans Lymphoma, Non-Hodgkin / drug therapy Lymphoma, Non-Hodgkin / genetics* Lymphoma, Non-Hodgkin / metabolism Lymphoma, Non-Hodgkin / pathology Methotrexate / pharmacology* Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| IF | 2.933 |
| 引用数 | 2 |
| リソース情報 | |
| ヒト・動物細胞 | HKBML(RCB0820) RAJI(RCB1647) |